GSK Blasts Teva's Rehearing Bid In $235M Verdict Fight
GlaxoSmithKline has urged the Federal Circuit to reject Teva Pharmaceuticals' bid for the full court to reconsider its decision to revive a jury's $235 million verdict in an induced infringement case...To view the full article, register now.
Already a subscriber? Click here to view full article